International Flavors & Fragrances
IFF
$84.28
+1.07%
International Flavors & Fragrances Inc. (IFF) is the world's largest specialty ingredients producer, supplying proprietary formulations and custom solutions to the food, beverage, health, household goods, personal care, and pharmaceutical industries. The company operates through four segments—Taste, Scent, Health & Biosciences, and Food Ingredients—with the latter two representing significant profit contributors and a planned divestiture of Food Ingredients expected to close in 2027. Currently, the stock is in focus due to its strategic portfolio reshaping, a recent earnings beat that drove a sharp price surge, and analyst optimism about margin recovery and growth in high-margin segments like Health & Biosciences.…
IFF
International Flavors & Fragrances
$84.28
Related headlines
IFF 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on International Flavors & Fragrances's 12-month outlook, with a consensus price target around $95.66 and implied upside of +13.5% versus the current price.
Average Target
$95.66
0 analysts
Implied Upside
+13.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$76 - $105
Analyst target range
IFF is covered by 18 analysts, with a consensus recommendation of 'Buy' (mean rating 1.65 on a 1-5 scale, where 1 is Strong Buy). The average price target is $91.54, implying an 8.3% upside from the current price of $84.55. The target range is wide, from a low of $71.00 to a high of $105.00, reflecting divergent views on the company's growth prospects and the impact of the planned Food Ingredients divestiture. Recent ratings from major firms like Morgan Stanley, Citigroup, and JP Morgan have been Overweight/Buy, with no downgrades in the past three months, indicating a positive sentiment shift. The wide spread between the low and high targets suggests high uncertainty, but the consensus leans bullish, supported by the company's strategic focus on higher-margin segments and expected margin expansion.
Bulls vs Bears: IFF Investment Factors
IFF presents a mixed picture: strong operational improvements and strategic reshaping are offset by persistent revenue declines and high debt. The bull case is supported by margin expansion, a positive earnings surprise, and a discounted valuation, while the bear case highlights top-line weakness and execution risks. Currently, the bull side has stronger evidence, as the market is pricing in a successful turnaround, but the key tension is whether revenue growth can resume to justify the forward PE of 17.6x. If revenue stabilizes and margins continue to expand, the stock could re-rate higher; if not, the valuation could compress.
Bullish
- Strong Earnings Beat and Margin Expansion: Q1 2026 EPS of $0.66 swung from a loss of $3.98 in Q1 2025, with gross margin expanding to 37.1% from 36.4% and operating margin improving to 10.2% from a negative figure. This demonstrates successful cost discipline and a favorable mix shift toward higher-margin segments.
- Strategic Portfolio Reshaping: The planned divestiture of the Food Ingredients segment, expected to close in 2027, will streamline operations and focus on high-margin businesses like Health & Biosciences, which generates 30% of profits. This could unlock value and improve overall profitability.
- Undervalued on Price-to-Sales: The PS ratio of 1.58x is well below the sector average of 2.1x and near the bottom of its five-year range (6.0x-12.7x), suggesting the market is pricing in significant challenges, but also offering substantial upside if the turnaround succeeds.
- Positive Analyst Sentiment: With a consensus rating of 'Buy' (mean 1.65) and an average price target of $91.54, analysts see an 8.3% upside. Recent ratings from major firms like Morgan Stanley and Citigroup are Overweight/Buy, with no downgrades in the past three months.
Bearish
- Revenue Decline Persists: Q1 2026 revenue fell 3.6% YoY to $2.741 billion, marking continued top-line contraction. While sequential improvement is positive, the lack of growth could limit earnings recovery and justify a lower valuation.
- High Debt and Interest Burden: Despite deleveraging, IFF still carries significant debt with $44 million in quarterly interest expense. The EV/EBITDA ratio of 29.9x is elevated, indicating the market is paying a premium for the company's earnings power, which could be risky if margins don't improve.
- Negative Trailing EPS: The trailing twelve-month EPS is -$0.02, and the PE ratio is negative, making traditional valuation metrics unreliable. This reflects the company's recent struggles and could deter value investors.
- Execution Risk in Divestiture: The planned divestiture of Food Ingredients carries execution risk, including potential regulatory hurdles, tax implications, and disruption to ongoing operations. Any delays or unfavorable terms could negatively impact the stock.
IFF Technical Analysis
IFF's stock has been in a strong uptrend over the past year, with a 1-year price change of +27.8%, significantly outperforming the S&P 500's +21.5% over the same period. The current price of $84.55 sits at 97.3% of its 52-week range (low $59.14, high $86.86), indicating the stock is trading near its highs, which reflects robust momentum but also potential overextension. The stock's beta of 0.94 suggests slightly lower volatility than the market, providing some cushion in turbulent conditions.
Beta
0.94
0.94x market volatility
Max Drawdown
-23.1%
Largest decline past year
52-Week Range
$59-$89
Price range past year
Annual Return
+27.4%
Cumulative gain past year
| Period | IFF Return | S&P 500 |
|---|---|---|
| 1m | +9.2% | +2.5% |
| 3m | +12.0% | +2.7% |
| 6m | +3.6% | +11.1% |
| 1y | +27.4% | +20.5% |
| ytd | +23.9% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IFF Fundamental Analysis
In Q1 2026, IFF reported revenue of $2.741 billion, a 3.6% year-over-year decline, but this was an improvement from the prior quarter's $2.589 billion, indicating a sequential recovery. The company swung to a net income of $169 million (EPS $0.66) from a loss of $1.018 billion in Q1 2025, driven by a one-time impairment charge in the prior year. Gross margin expanded to 37.1% from 36.4% in Q1 2025, and operating margin improved to 10.2% from a negative figure, reflecting cost discipline and a favorable mix shift toward higher-margin segments like Health & Biosciences and Scent. The balance sheet shows a debt-to-equity ratio of 0.47, down from 0.75 a year ago, and free cash flow of $92 million in Q1 2026, though the company still carries significant debt, with interest expense of $44 million in the quarter.
Quarterly Revenue
$2.7B
2026-03
Revenue YoY Growth
-3.6%
YoY Comparison
Gross Margin
37.1%
Latest Quarter
Free Cash Flow
$398000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IFF Overvalued?
Given that IFF's trailing twelve-month net income is negative (EPS -$0.02), the price-to-sales (PS) ratio is the most appropriate valuation metric, currently at 1.58x, which is below the sector average of 2.1x, indicating a discount. The forward PE of 17.6x suggests the market expects a strong earnings recovery, with consensus EPS estimates of $5.32 for the next fiscal year. Historically, IFF's PS ratio has ranged from 6.0x to 12.7x over the past five years, so the current 1.58x is near the bottom of its historical band, implying the market is pricing in significant operational challenges or a structural de-rating, but also offering potential upside if the turnaround succeeds.
PE
-46.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~340x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: IFF's high debt load, with a debt-to-equity ratio of 0.47 and quarterly interest expense of $44 million, poses a risk if cash flows weaken. The company's free cash flow of $92 million in Q1 2026 is modest relative to its debt, and the negative trailing EPS (-$0.02) indicates that profitability is not yet fully recovered. Revenue concentration in cyclical end-markets like food and personal care adds vulnerability to demand fluctuations, and the planned divestiture could disrupt operations and create uncertainty.